符合线路SPECT^18F—FDG显像在淋巴瘤患者诊断及监测复发中的意义

本研究探讨符合线路SPECT^18F—FDG显像检查对淋巴瘤患者诊断及治疗后监测复发的应用价值。回顾性分析我院1998—2008年病理活检和免疫组织化学确诊的淋巴瘤患者71例次的SPECT／PET检查结果。结果表明：28例患者初次治疗前行SPECT／PET检查的准确率100％，而CT准确率为81．7％。SPECT／PET和CT对病灶的检出灵敏度分别为85．7％和53．5％，两者有显著性差异（P=0．003）。SPECT／PET和CT对结外病灶的检出灵敏度分别为91．3％和56．5％，两者有显著性差异（P=0．007）。32例淋巴瘤患者在治疗结束后随访阶段共进行了43例次SPECT／PET检查。SPECT／PET对复发的阳性预测值为100％、阴性预测值为92．9％。6例患者为SPECT／PET先于临床症状、体征及其他实验室、影像学检查发现疾病复发。结论：SPECT／PET检查结果对淋巴瘤患者诊断和监测复发有重要意义。

Application of SPECT/PET in Patients with Lymphoma and Its Significance in Monitoring Relapse

The aim of this study was to evaluate the application value of SPECT/PET ^18F - FDG imaging in patients with lymphoma and its significance in monitoring relapse of this disease. A retrospective analysis of 71 SPECT/PET examinations was performed in patients with lymphoma diagnosed by pathologic and immunohistochemistric means from 1998 to 2008 in Peking university first hospital. The results showed that 28 patients underwent SPECT/PET before initial therapy, the accuracy of SPECT/PET and CT were 100% and 81.7% respectively. The diagnostic sensitivity of SPECT/PET and CT for foci were 85.7% and 53.5% respectively, and there was significant difference between them （p =0.003 ）. The diagnostic sensitivity of SPECT/PET and CT for extranodal foci were 91.3% and 56.5% respectively, there was significant difference also between them （p = 0. 007 ）. 32 patients underwent 43 SPECT/PET for monitoring relapse during follow up. The positive predictive value and negative predictive value of SPECT/PET for relapse were 100% and 92.9% respectively. The relapse were found by SPECT/PET in 6 patients more early than appearence of clinical symptoms and physical signs as well as laboratory examination, imaging examination, In conclusion, SPECT/ PET has significant value in diagnosing and monitoring relapse for patients with lymphoma.